Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

Strassnig, 2015, Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity, Schizophr Res, 165, 76, 10.1016/j.schres.2015.03.033 Keefe, 2005, Defining a cognitive function decrement in schizophrenia, Biol Psychiatry, 57, 688, 10.1016/j.biopsych.2005.01.003 Dauvermann, 2017, Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research, Br J Pharmacol, 174, 3136, 10.1111/bph.13919 Balu, 2015, The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond, Curr Opin Pharmacol, 20, 109, 10.1016/j.coph.2014.12.004 Javitt, 2009, Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification, Cur Opin Drug Discovery Dev, 12, 468 Chang, 2020, Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials, J Psychopharmacol, 34, 495, 10.1177/0269881120908016 Lin, 2017, Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial, World J Biol Psychiatry, 18, 357, 10.3109/15622975.2015.1117654 Bugarski-Kirola, 2017, Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies, Biol Psychiatry, 82, 8, 10.1016/j.biopsych.2016.11.014 Bugarski-Kirola, 2016, Lancet Psych, 3, 1115, 10.1016/S2215-0366(16)30344-3 Bugarski-Kirola, 2014, A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study, Eur Neuropsychopharmacol, 24, 1024, 10.1016/j.euroneuro.2014.03.007 Rosenbrock, 2018, Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: translational studies, Clin Transl Sci, 11, 616, 10.1111/cts.12578 Moschetti, 2018, Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study, Eur J Drug Metab Pharmacokinet, 43, 239, 10.1007/s13318-017-0440-z Moschetti, 2018, Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, phase I study investigating safety and pharmacokinetics, Clin Drug Investig, 38, 737, 10.1007/s40261-018-0660-2 Tsuda, 2019, Pharmacokinetics of single doses of BI 425809 in healthy Chinese and Japanese subjects: a randomized study, Clin Ther, 41, 961, 10.1016/j.clinthera.2019.03.014 Umbricht, 2018, Nailing the right dose! The key for developing glycine transporter inhibitors for schizophrenia, Biol Psychiatry, 84, 394, 10.1016/j.biopsych.2018.07.006 Winter, 2016, Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats, Exp Hematol, 44, 964, 10.1016/j.exphem.2016.07.003 Kern, 2011, The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study, Schizophr Res, 126, 124, 10.1016/j.schres.2010.11.008 Haig, 2016, A randomized trial to assess the efficacy and safety of ABT-126, a selective a7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia, Am J Psychiatry, 173, 827, 10.1176/appi.ajp.2015.15010093 Walling, 2016, Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia, Schizophr Bull, 42, 335, 10.1093/schbul/sbv072 Brown, 2019, Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial, Schizophr Bull, 45, 350, 10.1093/schbul/sby049 Keefe, 2015, Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia, Neuropsychopharmacology, 40, 3053, 10.1038/npp.2015.176 Brannan, 2019, Two global phase III trials of encenicline for cognitive impairment in chronic schizophrenia patients: red flags and lessons learned, Schizophr Bull, 45, S141, 10.1093/schbul/sbz022.133 Haig, 2014, A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia, Schizophr Bull, 40, 1433, 10.1093/schbul/sbt240 Keefe, 2018, Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms, J Clin Psychiatry, 79, 10.4088/JCP.17m11753 Georgiades, 2017, Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients, Schizophr Res, 190, 172, 10.1016/j.schres.2017.03.040 Keefe, 2017, Placebo response and practice effects in schizophrenia cognition trials, JAMA Psychiatry, 74, 807, 10.1001/jamapsychiatry.2017.1574 Harvey, 2020, Evaluation of the efficacy of BI 425809 pharmacotherapy in patients with schizophrenia receiving computerized cognitive training: methodology for a double-blind, randomized, parallel-group trial, Clin Drug Investig, 40, 377, 10.1007/s40261-020-00893-8 Buchanan, 2005, A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia, Schizophr Bull, 31, 5, 10.1093/schbul/sbi020 Umbricht, 2014, Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study, JAMA Psychiatry, 71, 637, 10.1001/jamapsychiatry.2014.163 Buchanan, 2011, The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?, Schizophr Bull, 37, 1209, 10.1093/schbul/sbq038 Keefe, 2016, Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in schizophrenia, Schizophr Bull, 42, 19